4-Chloroquinazolin-6-ol: Properties, Synthesis & Applications

4-Chloroquinazolin-6-ol is a halogenated bicyclic heterocyclic compound serving as a versatile and reactive building block in medicinal chemistry and pharmaceutical research.

IUPAC Name

4-chloroquinazolin-6-ol

Molecular Formula

C₈H₅ClN₂O

Core Scaffold

Quinazoline (benzopyrimidine) bicyclic ring system

Key Functional Groups

C-4 chloro (electrophilic site) and C-6 hydroxyl (nucleophilic/modifiable site)

Primary Research Use

Intermediate for kinase inhibitor and anticancer agent synthesis

Aladdin SKU

C177619

Chemical Structure and Properties

4-Chloroquinazolin-6-ol belongs to the quinazoline family of nitrogen-containing bicyclic heterocycles, comprising a benzene ring fused to a pyrimidine ring. Its molecular formula is C₈H₅ClN₂O. The compound features two strategically positioned reactive sites: a chlorine atom at the C-4 position and a hydroxyl group at the C-6 position.

The C-4 chloro substituent renders this position highly electrophilic, making it susceptible to nucleophilic aromatic substitution (SNAr) reactions with amines, thiols, and alkoxides under mild conditions. This reactivity is a direct consequence of the electron-withdrawing character of the adjacent ring nitrogen atoms, which activate the ring toward nucleophilic attack. The C-6 hydroxyl group, on the other hand, can participate in O-alkylation, O-acylation, or be converted to other leaving groups, providing orthogonal handles for sequential functionalization of the scaffold.

These dual reactive sites make 4-Chloroquinazolin-6-ol an exceptionally flexible intermediate for constructing diverse libraries of quinazoline derivatives in drug discovery programs.

Synthetic Utility and Functionalization Strategies

The primary synthetic value of 4-Chloroquinazolin-6-ol lies in its ability to undergo sequential, chemoselective transformations at its two distinct reactive centers. In a typical synthetic sequence, the more reactive C-4 chloride is first displaced by an amine nucleophile under mild basic conditions to install an amino group, yielding 4-amino-6-hydroxyquinazoline derivatives. The C-6 hydroxyl can subsequently be modified in a second step.

Alternatively, the hydroxyl group can be protected or pre-functionalized before displacement of the C-4 chloride, allowing access to products that would otherwise be difficult to obtain selectively. Common transformations of the C-6 hydroxyl include O-alkylation with alkyl halides or tosylates under basic conditions, conversion to a triflate for palladium-catalyzed cross-coupling reactions, and O-acylation to introduce ester or carbamate functionalities.

Palladium-catalyzed cross-coupling methodologies, including Suzuki-Miyaura, Buchwald-Hartwig, and Sonogashira couplings, can also be applied to related halogenated quinazoline scaffolds, though direct application to the C-4 chloride typically requires more reactive partners or optimized catalyst systems due to the sp²-hybridized C–Cl bond character in this heterocyclic context.

Research Applications in Drug Discovery

Quinazoline derivatives represent one of the most clinically validated heterocyclic scaffolds in modern medicinal chemistry. Several approved therapeutic agents, including EGFR-targeting kinase inhibitors used in oncology, are built upon the quinazoline core. 4-Chloroquinazolin-6-ol is therefore a strategically important intermediate for researchers synthesizing novel quinazoline-based drug candidates.

The compound is particularly relevant in the design of receptor tyrosine kinase (RTK) inhibitors, where the quinazoline ring system often serves as the hinge-binding element within the ATP-binding pocket of the target kinase. Substituents introduced via displacement of the C-4 chloride can modulate selectivity and potency, while modifications at C-6 can influence pharmacokinetic properties such as solubility, metabolic stability, and membrane permeability.

Beyond kinase inhibitor programs, quinazoline-6-ol derivatives have been reported in the literature as intermediates toward compounds with potential antibacterial, antifungal, and anti-inflammatory activities, reflecting the broad biological relevance of this scaffold class. Researchers in combinatorial and medicinal chemistry routinely employ building blocks such as 4-Chloroquinazolin-6-ol to populate compound libraries for high-throughput screening campaigns.

Handling, Storage, and Laboratory Safety

As with most halogenated heterocyclic intermediates, 4-Chloroquinazolin-6-ol should be handled with standard laboratory precautions. Personnel should wear appropriate personal protective equipment (PPE), including nitrile gloves, safety glasses, and a laboratory coat. Operations generating dust or aerosols should be conducted inside a well-ventilated fume hood.

The compound should be stored in a cool, dry, well-ventilated location, away from moisture, heat, and incompatible materials such as strong oxidizing agents and strong bases. Sealed containers under an inert atmosphere (nitrogen or argon) are recommended to minimize potential hydrolysis of the reactive C-4 chloride over prolonged storage periods.

Researchers should consult the current Safety Data Sheet (SDS) supplied by Aladdin Scientific (SKU C177619) for authoritative and up-to-date hazard classifications, first-aid measures, disposal procedures, and regulatory information prior to use. Specific toxicological data for this compound may be limited; appropriate precautionary measures consistent with handling reactive halogenated heterocycles should be applied in the absence of complete data.

Frequently asked questions

What makes 4-Chloroquinazolin-6-ol useful as a synthetic intermediate?

The compound possesses two orthogonal reactive sites—an electrophilic C-4 chloride susceptible to nucleophilic aromatic substitution and a C-6 hydroxyl amenable to alkylation, acylation, or further functionalization—allowing chemists to build structurally diverse quinazoline derivatives in a stepwise, controlled manner.

Why is the quinazoline scaffold important in drug discovery?

Quinazoline is one of the most clinically validated heterocyclic frameworks in medicinal chemistry. Multiple approved drugs, particularly EGFR kinase inhibitors in oncology, incorporate the quinazoline core. Its nitrogen atoms and ring geometry enable effective interactions with kinase ATP-binding pockets, making it a privileged scaffold for designing selective enzyme inhibitors.

How should 4-Chloroquinazolin-6-ol be stored to maintain its integrity?

The compound should be stored in a tightly sealed container under an inert atmosphere (nitrogen or argon) in a cool, dry environment away from moisture and incompatible materials. These conditions minimize hydrolysis of the reactive C-4 chloride and degradation of the hydroxyl functionality over time.

Can 4-Chloroquinazolin-6-ol be used in palladium-catalyzed cross-coupling reactions?

The C-4 chloride can in principle participate in palladium-catalyzed cross-coupling reactions such as Suzuki-Miyaura or Buchwald-Hartwig couplings, though the reactivity of aryl chlorides in such reactions typically requires optimized catalyst systems or more reactive coupling partners compared with aryl bromides or iodides. Additionally, the C-6 hydroxyl can be converted to a triflate, which is highly reactive in cross-coupling processes.

References

1. Comprehensive review of quinazoline derivatives in medicinal chemistry and their role as kinase inhibitor scaffolds.
2. General reference: March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure. Smith, M. B.; March, J. Wiley-Interscience.
3. Aladdin Scientific product page for 4-Chloroquinazolin-6-ol, SKU C177619. Aladdin Scientific Corp.

Products are supplied for research and development use only. Not for use in humans, animals, diagnosis, or therapy.